share_log

Tricida, Inc. (NASDAQ:TCDA) Sees Significant Drop in Short Interest

Tricida, Inc. (NASDAQ:TCDA) Sees Significant Drop in Short Interest

三股股份有限公司（NASDAQ：TCDA）認為短期利益大幅下降
Financial News Live ·  2023/01/01 05:21

Tricida, Inc. (NASDAQ:TCDA – Get Rating) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 10,820,000 shares, a decline of 22.7% from the November 30th total of 14,000,000 shares. Approximately 28.4% of the company's shares are short sold. Based on an average daily volume of 11,330,000 shares, the days-to-cover ratio is currently 1.0 days.

Tricida，Inc.(納斯達克代碼：TCDA-GET Rating)12月份空頭股數業務大幅下滑。截至12月15日，空頭股數共有1082萬股，比11月30日1400萬股的總數下降了22.7%。該公司約28.4%的股票被賣空。以日均成交量11,330,000股計算，目前天數與回補比率為1.0天。

Tricida Stock Down 11.9 %

Tricida股價下跌11.9%

Shares of NASDAQ TCDA traded down $0.02 during trading hours on Friday, reaching $0.15. The stock had a trading volume of 3,212,580 shares, compared to its average volume of 6,092,721. Tricida has a fifty-two week low of $0.13 and a fifty-two week high of $13.85. The firm has a 50-day moving average of $0.25 and a 200-day moving average of $7.23.

上週五交易時段，納斯達克天貓的股價下跌0.02美元，至0.15美元。該股成交量為3,212,580股，而其平均成交量為6,092,721股。Tricida的價格為0.13美元，為52周低點，52周高點為13.85美元。該公司的50日移動均線切入位在0.25美元，200日移動均線切入位在7.23美元。

Get
到達
Tricida
三叉戟
alerts:
警報：

Tricida (NASDAQ:TCDA – Get Rating) last announced its earnings results on Monday, November 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.10. Equities research analysts forecast that Tricida will post -1.88 earnings per share for the current year.

Tricida(納斯達克代碼：TCDA-GET Rating)最近一次公佈財報是在11月14日(星期一)。該公司公佈本季度每股收益(EPS)為0.44美元，比分析師普遍預期的0.54美元高出0.10美元。股票研究分析師預測，Tricida本年度每股收益將達到1.88美元。

Insider Buying and Selling at Tricida

Tricida的內幕買賣

In other Tricida news, Director Orbimed Advisors Llc sold 3,629,226 shares of Tricida stock in a transaction on Friday, November 25th. The stock was sold at an average price of $0.22, for a total value of $798,429.72. The transaction was disclosed in a filing with the SEC, which is available at
在Tricida的其他消息中，董事Orbimed Advisors LLC在11月25日(星期五)的一筆交易中出售了3,629,226股Tricida股票。這隻股票的平均售價為0.22美元，總價值為798,429.72美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可在
this link
這個環節
. In related news, Director Orbimed Advisors Llc sold 3,629,226 shares of the business's stock in a transaction on Friday, November 25th. The stock was sold at an average price of $0.22, for a total value of $798,429.72. The transaction was disclosed in a filing with the SEC, which is accessible through
。在相關新聞中，董事在11月25日(星期五)的一次交易中出售了3629,226股該公司股票。這隻股票的平均售價為0.22美元，總價值為798,429.72美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過
this link
這個環節
. Also, major shareholder Brian M. Isern sold 212,283 shares of the business's stock in a transaction on Wednesday, October 12th. The shares were sold at an average price of $12.53, for a total value of $2,659,905.99. Following the completion of the sale, the insider now owns 1,580,899 shares in the company, valued at approximately $19,808,664.47. The disclosure for this sale can be found
。此外，大股東Brian M.Isern在10月12日星期三的一次交易中出售了212,283股該公司的股票。這些股票的平均價格為12.53美元，總價值為2659,905.99美元。出售完成後，這位內部人士現在擁有該公司1,580,899股，價值約19,808,664.47美元。關於這次銷售的披露可以找到
here
這裏
. Over the last quarter, insiders have acquired 859,708 shares of company stock worth $9,591,203 and have sold 8,482,094 shares worth $5,870,783. Company insiders own 35.60% of the company's stock.
。在上個季度，內部人士購買了859,708股公司股票，價值9,591,203美元，出售了8,482,094股，價值5,870,783美元。公司內部人士持有該公司35.60%的股份。

Institutional Trading of Tricida

Tricida的機構交易

Large investors have recently made changes to their positions in the company. VR Adviser LLC raised its stake in Tricida by 26.9% during the 3rd quarter. VR Adviser LLC now owns 9,050,064 shares of the company's stock valued at $94,845,000 after acquiring an additional 1,917,985 shares during the last quarter. BlackRock Inc. raised its stake in Tricida by 37.6% during the 3rd quarter. BlackRock Inc. now owns 3,698,400 shares of the company's stock valued at $38,759,000 after acquiring an additional 1,009,907 shares during the last quarter. Deep Track Capital LP raised its stake in Tricida by 13.6% during the 1st quarter. Deep Track Capital LP now owns 2,652,693 shares of the company's stock valued at $21,805,000 after acquiring an additional 317,550 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in Tricida during the 1st quarter valued at approximately $17,115,000. Finally, Commodore Capital LP raised its stake in Tricida by 16.3% during the 2nd quarter. Commodore Capital LP now owns 2,028,453 shares of the company's stock valued at $19,635,000 after acquiring an additional 283,883 shares during the last quarter.

大型投資者最近對他們在該公司的頭寸進行了調整。VR諮詢公司LLC在第三季度增持了26.9%的Tricida股份。VR Adviser LLC在上個季度增持了1,917,985股後，現在擁有9,050,064股公司股票，價值94,845,000美元。貝萊德股份有限公司在第三季度增持了37.6%的天合光能股份。貝萊德股份有限公司在上個季度增持了1,009,907股後，目前持有該公司3,698,400股股票，價值38,759,000美元。第一季度，Deep Track Capital LP將其在Tricida的持股比例提高了13.6%。在上個季度增持了317,550股後，Deep Track Capital LP現在擁有該公司2,652,693股股票，價值21,805,000美元。弗雷澤生命科學管理公司在第一季度購買了Tricida的新股份，價值約17,115,000美元。最後，Commodore Capital LP在第二季度將其在Tricida的持股增加了16.3%。Commodore Capital LP在上個季度額外收購了283,883股後，現在擁有該公司2,028,453股股票，價值19,635,000美元。

Analysts Set New Price Targets

分析師設定新的價格目標

Several research analysts recently commented on TCDA shares. Needham & Company LLC cut Tricida from a "buy" rating to a "hold" rating in a research note on Tuesday, October 25th. Cowen cut Tricida from an "outperform" rating to a "market perform" rating in a research note on Monday, October 24th. JPMorgan Chase & Co. cut Tricida from a "neutral" rating to an "underweight" rating in a research note on Tuesday, October 25th. Finally, Cowen cut Tricida to a "market perform" rating in a research report on Monday, October 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $17.00.

幾位研究分析師最近對TcdA股發表了評論。Needham&Company LLC在10月25日星期二的一份研究報告中將Tricida的評級從“買入”下調至“持有”。考恩在10月24日週一的一份研究報告中將Tricida的評級從“跑贏大盤”下調至“市場表現”。摩根大通在10月25日星期二的一份研究報告中將Tricida的評級從中性下調至減持。最後，考恩在10月24日星期一的一份研究報告中將Tricida的評級下調至“市場表現”。一位研究分析師對該股的評級為賣出，三位分析師給出了持有評級，一位分析師給出了該公司的買入評級。根據MarketBeat的數據，該公司目前的平均評級為持有，平均目標價為17.00美元。

About Tricida

關於Tricida

(Get Rating)

(獲取評級)

Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.

Tricida，Inc.是一家制藥公司。它的重點是Vvermer(TRC101)的開發和商業化，這是一種非吸收的口服聚合物，已經完成了第三階段試驗，通過結合和去除胃腸道中的酸來治療慢性腎臟疾病患者的代謝性酸中毒。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on Tricida (TCDA)
  • MarketBeat: Week in Review 12/26 – 12/30
  • The Dogs Of Tech: It's Time For A Bite Of These Stocks
  • Does This Acquisition Make Microsoft a Bear Market Buy?
  • Should You Warm up to Generac Stock for the Winter?
  • Is Kintara Therapeutics A Hidden Gem?
  • 免費獲取StockNews.com關於Tricida的研究報告(TcdA)
  • MarketBeat：回顧一週12/26-12/30
  • 科技狗：是時候咬一口這些股票了
  • 這筆收購會讓微軟成為熊市買入者嗎？
  • 你應該熱身到Generac股票過冬嗎？
  • 金塔拉治療公司是一顆隱藏的寶石嗎？

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.

接受Tricida Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Tricida和相關公司的最新新聞和分析師評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論